Introduction

Soft tissue sarcoma (STS) is a rare mesenchymal-derived tumor that most often occurs in the extremities. It is subdivided into about 75 distinct subgroups with distinct biology, molecular abnormalities, and therapy responses. Due to the rarity of such cancers and their numerous varieties, no large-scale data exist to guide treatment, necessitating a multidisciplinary and customized approach1,2. The incidence of STS in senior individuals has been growing in recent years, as the world ages3,4. Recent research indicates that STS instances occur in people 65 years of age, with the frequency of sarcoma increasing with age, and there is no conclusive idea regarding the best complete treatment for senior STS patients5,6. The current studies overall, these studies suggest that surgery in combination with radiotherapy remains the best means of controlling STS today compared to other treatments. Although increasing age shows a negative correlation with STS-specific survival, the prognosis for elderly patients with STS is favorable when older patients of appropriate age are selected to undergo extensive STS resection7,8,9. According to a study monitoring the epidemiology of STS, the analysis showed that fewer patients ≥ 85.5 years of age underwent surgical treatment10. Furthermore, recent studies suggest that STS cases gradually rise in patients 65 years and older. Therefore, it is important to study the clinical-related prognostic factors in STS elderly groups.

Given the relatively rare incidence of STS, clinical studies for STS are typically difficult, necessitating a more rigorous design that includes patient screening and therapy assignment. The nomogram combines and illustrates several important prognostic factors, is a reliable and valid tool for quantifying individual risk, and performs well in predicting survival in various cancers. In previous studies, nomograms for STS in specific tumor primary locations or STS of specific histological types (e.g. liposarcoma, fibrosarcoma) have been developed11,3). In both the training and validation sets, DCA demonstrated the good clinical usefulness of the nomogram in predicting postoperative OS in elderly patients with STS, as shown in Fig. 4.

Figure 2
figure 2

Receiver operating characteristic curves for elderly patients with soft tissue sarcoma after surgical resection. (A) Training set, (B) Validation set.

Full size image
Figure 3
figure 3

Calibration of the nomogram model in the training set (A–C), and validation set (D–F), respectively.

Full size image
Figure 4
figure 4

Decision curve analysis of the nomogram model in the training set (A–C), and validation set (D–F), respectively.

Full size image

Risk classification system

The optimum cut-off point of the overall score based on OS was determined using X-tiles software, and all cases were classified into low risk (295), middle risk (295–340), and high risk (> 340) groups. Kaplan–Meier survival curves for each risk subgroup were plotted and log-rank tests were performed, which showed differences in OS among patients with different risk levels (P < 0.001) (Fig. 5). Patients in the high risk group had a worse outcome than those in the low risk group in the training and validation set. It suggests that the nomogram-based risk classification system seems to have a high predictive ability for the OS.

Figure 5
figure 5

Kaplan–Meier survival analyses were performed for comparing postoperative overall survival in the low risk, middle risk, and high risk subgroups of all patients in the training set (A) and validation set (B).

Full size image

Discussion

In this study, a clinical prediction model was constructed by the SEER database to predict postoperative OS in elderly patients with STS. The nomogram we created, as shown in Fig. 3, can accurately predict OS at 1, 3, and 5 years. This is the first study to use extensive and diverse case data to build a predictive nomogram model for elderly postoperative patients with STS. This prediction nomogram can easily predict patients’ prognosis, inform patients of the benefits of certain treatments, and have important implications for clinical decision-making.

It’s vital to keep in mind that not all groups of elderly adults with STS can be surgically treated. In the present results, the prognosis of elderly postoperative patients with STS > 82 years of age was worse compared to patients in the 73–82 years age group. It was similarly confirmed in previous single-center institutional studies that age is not a contraindication to surgery in elderly cancer patients with STS15,16,17. Buchner et al. prospectively studied 21 STS patients over the age of 70, and they discovered that even after surgery, these patients had a worse 5-year OS18. Lahat et al. analyzed 325 STS ≥ 65 years of age patients while selecting appropriate elderly patients among these individuals for surgery. They noted a decrease in bit survival after surgery in patients > 75 years of age. However, postoperative adverse effects and recovery time did not differ significantly between these STS age groups7. In another study it was also confirmed that surgery is safe and that reduced surgical use in the elderly may be an area of improved prognosis, while this study also noted a significant reduction in mortality in the elderly at 90 days after undergoing STS, suggesting that the postoperative 90-day period is key to the increased surgical risk affecting elderly patients with STS. Whether these factors influence surgical decision-making in elderly patients directly or indirectly19. Taken together, each of these studies concludes that despite the reduced OS in the elderly patient population after surgery compared to the younger patient population, surgery is still advisable for the relatively low perioperative complication rate and postoperative adverse effects in a subset of appropriate elderly patients with STS.

Whether tumors metastasize or not, disease stage and tumor size also have a different prognosis for elderly patients with STS after surgery. Elderly patients with STS who developed distant metastasis in this study had a poorer OS in comparison to elderly patients with localized tumors. The poorer prognosis after surgery in elderly patients with STS with tumor diameter size > 100 mm is an important disadvantage. Several studies to date have confirmed the prognostic factors associated with the diagnosis of STS in adults. In previous studies, the most common unfavorable prognostic factors for elderly postoperative patients with STS were found to be: (1) Site of tumor occurrence: including head, neck, and trunk, (2) different subtypes of tumors, (3) deeper tumor location, (4) residual tumor cells are still present at the surgical incision margin, (5) tumor size > 5 cm, and other factors20,21,22,23,24. Previous research has indicated that younger STS patients are more likely than older STS patients to develop tumors in a deeper position. Smaller tumor diameter and lower tumor grade were found to be independent risk variables for recurrence-free survival and OS in younger and older STS patients, even though older STS patients had larger tumors and a higher proportion of graded tumors25. Therefore, compared with younger patients with STS, older patients have relatively larger tumors, higher tumor stage, and grade, and are prone to distant metastases, causing some surgical difficulty and making surgical decisions difficult, which may also contribute to the poorer prognosis of older patients with STS.

Conclusion

We constructed and verified a predictive nomogram to estimate the personalized postoperative OS of elderly patients with STS. The nomogram allows clinical practitioners to more accurately evaluate the prognosis of individual patients, facilitates the progress of individualized treatment, and provides clinical guidance.